| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 17.112 | 16.420 | 21.165 | 18.598 | 13.664 | 24.180 | 25.601 | 31.464 | 27.104 | 2.652 |
| Total Income - EUR | 17.193 | 16.511 | 21.244 | 18.638 | 13.669 | 24.187 | 25.601 | 31.623 | 27.820 | 2.833 |
| Total Expenses - EUR | 17.410 | 18.112 | 18.813 | 19.395 | 17.651 | 16.235 | 21.754 | 15.057 | 29.995 | 11.706 |
| Gross Profit/Loss - EUR | -217 | -1.601 | 2.431 | -757 | -3.983 | 7.952 | 3.846 | 16.566 | -2.174 | -8.873 |
| Net Profit/Loss - EUR | -561 | -1.766 | 2.218 | -943 | -4.110 | 7.739 | 3.590 | 16.297 | -2.901 | -8.957 |
| Employees | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 |
Check the financial reports for the company - Dana-Homeo Med S.r.l.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 7.731 | 5.561 | 4.871 | 4.134 | 2.909 | 2.225 | 1.477 | 802 | 539 | 0 |
| Current Assets | 1.215 | 1.538 | 2.293 | 696 | 1.684 | 3.924 | 6.335 | 23.719 | 17.225 | 2.544 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 494 | 0 | 0 | 0 | 1.412 |
| Cash | 1.215 | 1.538 | 2.293 | 696 | 1.684 | 3.430 | 6.335 | 23.719 | 17.225 | 1.132 |
| Shareholders Funds | -481 | -2.239 | 21 | -923 | -5.015 | 2.835 | 6.434 | 22.750 | 15.789 | 2.544 |
| Social Capital | 67 | 66 | 64 | 63 | 62 | 61 | 61 | 61 | 60 | 60 |
| Debts | 9.427 | 9.338 | 7.144 | 5.753 | 9.609 | 3.314 | 1.377 | 1.771 | 1.975 | 0 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 5.0415 | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 |
| Main CAEN | "8621 - 8621" | |||||||||
| CAEN Financial Year |
8621
|
|||||||||
Comments - Dana-Homeo Med S.r.l.